AcquisitionOther
iBio, Inc. acquired Preclinical PD-1 Agonist Antibody Program to Otsuka
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
iBio, Inc. -> Preclinical PD-1 Agonist Antibody Program to Otsuka · $1 million
“The deal provides iBio with a potential significant new source of non-dilutive capital if all of the milestones are satisfied; further validates the ability of our precision-driven and deeply integrated technology stack to efficiently deliver antibody candida
Open source record (SEC) ↗